Skip to main content
Clinical Trials/2024-514713-35-00
2024-514713-35-00
Completed
Phase 1

A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail

Pharvaris Netherlands B.V.1 site in 1 country14 target enrollmentJuly 29, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Pharvaris Netherlands B.V.
Enrollment
14
Locations
1
Status
Completed
Last Updated
last year